TBIQYR863-Global Antivenom Market Research Report 2019
- TBI242916
- February 04, 2019
- Global
- 97 pages
- QY Market Research
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings. They are only recommended if there is significant toxicity or a high risk of toxicity. The specific antivenom needed depends on the species involved. It is given by injection.
Asia-Pacific Antivenom market is valued at 285.00 million USD in 2017 and is expected to reach 359.23 million USD by the end of 2023, growing at a CAGR of 43.93% between 2016 and 2022.
The price of Antivenom is slightly increased in nearly five years. For being accorded with the corresponding application area, the product price has a large differences.
Despite the presence of competition problems, due to the global recovery trend is clear, investors are still optimistic about this areas, the future will still have more new investment enter the field.
The global Antivenom market is valued at 830 million US$ in 2018 is expected to reach 1020 million US$ by the end of 2025, growing at a CAGR of 2.6% during 2019-2025.
This report focuses on Antivenom volume and value at global level, regional level and company level. From a global perspective, this report represents overall Antivenom market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
CSL Behring
Merck & Co.
BTG Plc
Pfizer
Haffkine Bio-Pharmaceutical Corporation
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
Segment by Regions
North America
Europe
China
Japan
Segment by Type
Polyvalent antivenom
Monovalent antivenom
Segment by Application
Retail Pharmacies
Hospitals
Others
Table of Contents
Executive Summary
1 Antivenom Market Overview
1.1 Product Overview and Scope of Antivenom
1.2 Antivenom Segment by Type
1.2.1 Global Antivenom Production Growth Rate Comparison by Type (2014-2025)
1.2.2 Polyvalent antivenom
1.2.3 Monovalent antivenom
1.3 Antivenom Segment by Application
1.3.1 Antivenom Consumption Comparison by Application (2014-2025)
1.3.2 Retail Pharmacies
1.3.3 Hospitals
1.3.4 Others
1.3 Global Antivenom Market by Region
1.3.1 Global Antivenom Market Size Region
1.3.2 North America Status and Prospect (2014-2025)
1.3.3 Europe Status and Prospect (2014-2025)
1.3.4 China Status and Prospect (2014-2025)
1.3.5 Japan Status and Prospect (2014-2025)
1.3.6 Southeast Asia Status and Prospect (2014-2025)
1.3.7 India Status and Prospect (2014-2025)
1.4 Global Antivenom Market Size
1.4.1 Global Antivenom Revenue (2014-2025)
1.4.2 Global Antivenom Production (2014-2025)
2 Global Antivenom Market Competition by Manufacturers
2.1 Global Antivenom Production Market Share by Manufacturers (2014-2019)
2.2 Global Antivenom Revenue Share by Manufacturers (2014-2019)
2.3 Global Antivenom Average Price by Manufacturers (2014-2019)
2.4 Manufacturers Antivenom Production Sites, Area Served, Product Types
2.5 Antivenom Market Competitive Situation and Trends
2.5.1 Antivenom Market Concentration Rate
2.5.2 Antivenom Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion
3 Global Antivenom Production Market Share by Regions
3.1 Global Antivenom Production Market Share by Regions
3.2 Global Antivenom Revenue Market Share by Regions (2014-2019)
3.3 Global Antivenom Production, Revenue, Price and Gross Margin (2014-2019)
3.4 North America Antivenom Production
3.4.1 North America Antivenom Production Growth Rate (2014-2019)
3.4.2 North America Antivenom Production, Revenue, Price and Gross Margin (2014-2019)
3.5 Europe Antivenom Production
3.5.1 Europe ...
| read more...
Related Reports
Global Anti-Venom Market Research Report 2019 (Includes Business Impact of COVID-19)
Published : 20, March
Published : 20, March